Research & Education

Centrally Located Early-Stage Lung Cancer: When and How to Perform Stereotactic Ablative Radiotherapy (SABR)

Thursday, March 24, 2016 - 4 p.m. Central European Time - Recording Available

The IASLC Education Committee is pleased to announce the first program in the 2016 series of Live Webinars presented by the Advanced Radiation Therapy (ART) Committee. This subcommittee is focused on the development and execution of educational and informational programs addressing state of the art radiation therapy for lung cancer. This live program will be moderated by Francoise Mornex, MD, PhD and feature presentations by Suresh Senan, MD, PhD, FRCR, and Wilko Verbakel, PhD, Ir, PEDng.

Françoise MORNEX Suresh Senan Wilko Verbakel 

Program Chair
PR Françoise Mornex , MD, PhD

Département de Radiothérapie
Centre Hospitalier Lyon Sud
LYON, France

Suresh Senan, MD, PhD, FRCR

Department of Radiation Oncology
VU University Medical Center
Amsterdam, Netherlands

Wilko Verbakel, PhD, Ir, PDEng

Medical Physicist
Department of Radiation Oncology
VU University Medical Center
Amsterdam, Netherlands

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

Name of Planner(s): 

 

    Deb Whippen-Nothing to Disclose

Name of Activity: 

 

Centrally Located Early-Stage Lung Cancer: When and How to Perform Stereotactic Ablative Radiotherapy (SABR)

Date of Activity:

 

March 24, 2016

Faculty/Speaker(s):

Financial DISCLOSURES

COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

 

 

 

PR Françoise Mornex , MD, PhD-Consulting for: Lilly, Roche and Boehringrt-Ingelheim

Suresh Senan, MD, PhD, FRCR –Honoraria and Research support by Varian Medical Systems

Wilko Verbakel, PhD, Ir, PDEng- Honoraria and Research support by Varian Medical Systems

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)xxxx

 Internet Enduring Material

Are there Commercial Supporters for this activity?

     Yes  

If yes, please list: Grant support for this webinar received by Elekta

 

SABR is a guideline-specified curative treatment for peripheral lung tumors, but its use in central lung tumors is less well established. ESMO guidelines define SABR by use of a minimal radiation dose of BED10 >100 Gy. Centrally-located lung tumors can be classified as either "moderately central" or "ultra-central," with the former defined as those adjacent to, but not invading, central structures such as the bronchi or hilar blood vessels. In contrast, "ultra-central" lung tumors refer to central NSCLC where the planning target volume (PTV) overlaps the trachea or main bronchi.

Growing data from both retrospective studies and prospective trials attest to high local control rates and limited toxicity when SABR is used for 'moderately central' tumors. In contrast, the use of SABR for "ultra-central" tumors has been associated with higher rates of serious and fatal toxicity. This webinar will review the available data on clinical outcomes (toxicity, local control), and describe the practical aspects for treatment planning and delivery for such tumors.

This 60-minute program will be an interactive event and there will be ample opportunity for attendees to e-mail their questions and comments to the faculty for fruitful exchange.

Central Lung Tumors: Definitions and Clinical Outcomes After SABR - Suresh Senan, MD, PhD, FRCR

Treatment Planning, Delivery and Verification for Central Lung SABR - Wilko Verbakel, PhD, Ir, PDEng

At the end of this activity participants will be able to:

  1. Define  central structures such as the bronchi or hilar blood vessels.
  2. Attest to high local control rates and limited toxicity when SABR is used for 'moderately central' tumors.
  3. Review the available data on clinical outcomes (toxicity, local control), and describe the practical aspects for treatment planning and delivery for such tumors.

DOWNLOAD RECORDING

CME Information:

Financial/Commercial Relationships DISCLOSURES

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

SABR is a guideline-specified curative treatment for peripheral lung tumors, but its use in central lung tumors is less well established. ESMO guidelines define SABR by use of a minimal radiation dose of BED10 >100 Gy. Centrally-located lung tumors can be classified as either "moderately central" or "ultra-central," with the former defined as those adjacent to, but not invading, central structures such as the bronchi or hilar blood vessels. In contrast, "ultra-central" lung tumors refer to central NSCLC where the planning target volume (PTV) overlaps the trachea or main bronchi.

Growing data from both retrospective studies and prospective trials attest to high local control rates and limited toxicity when SABR is used for 'moderately central' tumors. In contrast, the use of SABR for "ultra-central" tumors has been associated with higher rates of serious and fatal toxicity. This webinar will review the available data on clinical outcomes (toxicity, local control), and describe the practical aspects for treatment planning and delivery for such tumors.

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Thank you for your participation.

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME Credit is only available for those that participate in the Live Session.

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Thursday, March 24, 2016 at 11:00:00 AM EST UTC-4 hours
Amsterdam (Netherlands) Thursday, March 24, 2016 at 4:00:00 PM CET UTC+1 hour
Paris (France) Thursday, March 24, 2016 at 4:00:00 PM CET UTC+1 hour
London (United Kingdom - England) Thursday, March 24, 2016 at 3:00:00 PM GMT UTC
Rome (Italy) Thursday, March 24, 2016 at 4:00:00 PM CET UTC+1 hour
Madrid (Spain) Thursday, March 24, 2016 at 4:00:00 PM CET UTC+1 hour
Berlin (Germany) Thursday, March 24, 2016 at 4:00:00 PM CET  UTC+1 hour
Moscow (Russia) Thursday, March 24, 2016 at 6:00:00 PM MSK UTC+3 hours
Dublin (Ireland) Thursday, March 24, 2016 at 3:00:00 PM GMT UTC
Corresponding UTC (GMT) Thursday, March 24, 2016 at 03:00:00 PM    

How to use the Time Zone Converter